Micromet, Inc. Elects Joseph P. Slattery to Board of... (blic offering assumed the position ofSen...)

Micromet, Inc. Elects Joseph P. Slattery to Board of Directors

Date:11/14/2007

blic offering, assumed the position of Senior Vice President of Finance and Information Systems in 2002, and was promoted to Chief Financial Officer in October 2006. Before joining Digene, Mr. Slattery served as an audit manager at KPMG and as a staff auditor at Ernst & Young. He holds a B.S. degree in accounting from Bentley College and is a certified public accountant.

The Company and Mr. Schneider anticipate that Mr. Schneider will enter into a consulting agreement with the Company pursuant to which he will assist the Company in ensuring an efficient transition of the audit committee chair responsibilities to Mr. Slattery.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody in Micromet's product pipeline developed utilizing the BiTE(R) antibody technology platform, is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of Astra Zeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. KGI Elects Three New Members to Board of Trustees
3. The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
4. Genaera Elects New Board Member and Announces Executive Appointments
5. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
6. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
7. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
10. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member

Post Your Comments:

Micromet, Inc. Elects Joseph P. Slattery to Board of...(blic offering assumed the position ofSen...)